Most cardiac operations involve the use of extracorporeal circulation with its
attendant systemic inflammatory response syndrome. Many anti-inflammatory strategies
hold promise for reducing the associated morbidity of cardiopulmonary bypass. The
application of pharmacological and mechanical strategies to control this
inflammatory response now has demonstrable clinical benefit. The additional costs of
these successful strategies are offset by the economic savings and improved quality
of care.
Get full access to this article
View all access options for this article.
References
1.
Van de Watering LM, Hermans J, Houbiers JGet al.Beneficial effects of leukocyte depletion of transfused blood on
postoperative complications in patients undergoing cardiac surgery: a
randomized clinical trial. Circulation1998; 97: 562-568.
2.
Kirklin JK.Prospects for understanding and eliminating the deleterious effects of
cardiopulmonary bypass. Ann Thorac Surg1991; 51: 529-531.
3.
Gott JP, Cooper WA, Schmidt FE Jret al.Modifying risk for extracorporeal circulation: trial of four
antiinflammatory strategies. Ann Thorac Surg1998; 66: 747-754.
4.
Eagle KA, Guyton RA, Davidoff Ret al.ACC/AHA Guidelines for coronary artery bypass graft surgery. J Am Coll Cardiology1999; 1262-1347.
5.
Hill G, Alonso A, Spurzem J, Stammers A, Robbins R.Aprotinin and methylprednisolone equally blunt cardiopulmonary
bypass-induced inflammation in humans. J Thorac Cardiovasc Surg1995; 110: 1658-1662.
6.
Thorn GW.Clinical considerations in the use of corticosteroids [special article]. N Engl J Med1996; 274: 775-781.
7.
Lasser EC, Berry CC, Talner LBet al.Pretreatment with corticosteroids to alleviate allergic reactions to
intravenous contrast material. N Engl J Med1987; 317: 845-849.
8.
Levy JH, Pifarre R, Schaff HVet al.A multicenter, double-blind, placebo-controlled trial of aprotinin for
reducing blood loss and the requirement for donor-blood transfusion in
patients undergoing repeat coronary artery bypass grafting. Circulation1995; 92: 2236-2244.
9.
Cosgrove DM, Heric G, Lytle BWet al.Aprotinin therapy for reoperative myocardial revascularization: a
randomized double-blinded, placebo-controlled study. Ann Thorac Surg1992; 54: 1031-1038.
10.
Asimakopoulos G, Thompson R, Nourshargh Set al.An antiinflammatory property of aprotinin detected at the level of
leukocyte extravasation. J Thorac Cardiovasc Surg2000; 120: 361-369.
11.
Murkin JM.Cardiopulmonary bypass and the inflammatory response: a role for serine
protease inhibitors?J Cardiothorac Vasc Anesth1997; 11(suppl. 1): 19-23.
12.
Jones DR, Hill RC, Hollingsed MJet al.Use of heparin-coated cardiopulmonary bypass. Ann Thorac Surg1993; 56: 566-568.
13.
Gu YJ, van Oeveren W, Akkerman C, Boonstra PW, Huyzen RJ, Wildevuur CRH.Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg1993; 55: 917-922.
14.
Redmond JM, Gillinov AM, Stuart RSet al.Heparin-coated bypass circuits reduce pulmonary injury. Ann Thorac Surg1993; 56: 474-479.
15.
Wagner WR, Johnson PC, Thompson KA, Marrone GC.Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and
postoperative blood loss. Ann Thorac Surg1994; 58: 734-741.
16.
Edmonds LH Jr.Surface-bound heparin - panacea or peril? [Editorial]. Ann Thorac Surg1994; 58: 285-286.
17.
Murphy PJ, Connery C, Hicks GL Jr, Blumberg N.Homologous blood transfusion as a risk factor for postoperative infection
after coronary artery bypass graft operations. J Thorac Cardiovasc Surg1992; 104: 1092-1099.
18.
Jensen LS, Kissmeyer-Nielson P, Wolff B, Qvist N.Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood
transfusion and complications after colorectal surgery. Lancet1996; 348: 841-885.
Blumberg N, Triulzi DJ, Heal JM.Transfusion-induced immunomodulation and its clinical consequences. Transfusion Medicine Reviews1990; 4(suppl. 1): 24-35.
21.
Lazar HL, Zhang X, Hamasaki Tet al.Role of leukocyte depletion during cardiopulmonary bypass and cardioplegic arrest. Ann Thorac Surg1995; 60: 1745-1748.
22.
Pearl JM, Drinkwater DC, Laks H, Capouya ER, Gates RN.Leukocyte-depleted reperfusion of transplanted human hearts: a randomized,
double-blind clinical trial. J Heart Lung Transplant1992; 11: 1082-1092.
23.
Byrne JG, Appleyard RF, Lee CCet al.Controlled reperfusion of the regionally ischemic myocardium with
leukocyte-depleted blood reduces stunning, the no-reflow phenomenon, and
infarct size. J Thorac Cardiovasc Surg1992; 103: 66-72.
24.
Sawa Y, Matsuda H, Shimazaki Yet al.Evaluation of leukocyte-depleted terminal blood cardioplegic solution in
patients undergoing elective and emergency coronary artery bypass grafting. J Thorac Cardiovasc Surg1994; 108: 1125-1131.
25.
Gu YJ, deVries AJ, Boonstra PW, van Oeveren W.Leukocyte depletion results in improved lung function and reduced
inflammatory response after cardiac surgery. J Thorac Cardiovasc Surg1996; 112: 494-500.
